Skip to main content

Thermo Fisher Issues $800M of Senior Notes

NEW YORK (GenomeWeb) – Thermo Fisher Scientific issued $800 million in aggregate principal amount of 3.3 percent senior notes due in 2022, the company said in a document filed with the US Securities and Exchange Commission on Friday after the close of the market. 

The company announced its plans to offer the dollar-denominated notes and then priced them earlier this month. The company will use net proceeds principally to pay back debt, including the $400 million aggregate principal amount of its 3.25 percent senior notes due 2014 that mature on Nov. 20, it said. The company has also filed a registration document with the SEC for a euro-denominated offering of its senior notes due in 2025. 

The joint book-running managers for the offering are Merrill Lynch, Pierce, Fenner & Smith; Mitsubishi UFJ Securities; Citigroup Global Markets; and Credit Suisse Securities.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.